Trial Profile
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary) ; Epinephrine; Loratadine; Mometasone; Olopatadine
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors ALK-Abello; Merck Sharp & Dohme
- 08 Nov 2021 Results of pooled post hoc analysis comparing efficacy and safety of the HDM SLIT-tablet between adults and adolescents by using data from two studies (NCT01700192 an JapicCTI21848) presented at the 2021 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
- 01 Mar 2021 Results assessing efficacy and safety data from 2 clinical trials (NCT01700192 and JapicCTI121848), presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology